NF1 and melanoma: However, due to emergent resistance to single-agent RAFi in patients [43, 44], combination treatments of BRAFi (dabrafenib) with MEKi (trametinib) have been developed for melanomas [45] and are also being tested in pediatric patients with plexiform NF-1, BRAF-V600E refractory/relapsed tumors (NCT02124772).